SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy
Abstract The screening of non-small cell lung cancer (NSCLC) tumors for anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements is important because of the dramatically favorable therapy response to ALK inhibitor. However, the exact mechanism of poor survival in ALK fusion lung cancer...
Enregistré dans:
Auteurs principaux: | Xiaolin Ji, Yan Liu, Fang Mei, Xinyang Li, Mengxue Zhang, Buwen Yao, Rui Wu, Jiangfeng You, Fei Pei |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/35f4e8521f1a4246a6920b11d0ce5940 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
par: Ashiq Masood, et autres
Publié: (2021) -
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
par: Zhu VW, et autres
Publié: (2018) -
ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
par: Elena Corral de la Fuente, et autres
Publié: (2021) -
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
par: Deng L, et autres
Publié: (2018) -
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
par: Barrows SM, et autres
Publié: (2019)